RxDoctor Payments Data

Cody Delaney, PA

Surgical · Portsmouth, OHNPI 1811469968

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Endologix LLC at 32.9% of the total. Reporting peaked in 2022 at $1,105 and has fallen 92.8% since, to $80 in 2025. Among surgical clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,195in general payments, 2019–2025

Across 153 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$1K
  • Johnson & Johnson$494
  • Amgen$330
  • AbbVie$330
  • Smith+Nephew$224
  • Pfizer$140
  • plus $626 from 18 others

What the payments were for

  • Food & beverage$3,195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,195 in reported general payments places this provider in the 90th percentile of 294 surgical providers in Ohio.

See all surgical providers in Ohio

Medicare billing

Part B allowed, 2024
$69,230
Medicare patients
311
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban26$17,625
EliquisApixaban12$6,921
Pantoprazole Sodium85$579
Sucralfate43$499
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg24$417
ClopidogrelClopidogrel Bisulfate22$162
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen34$132
Metoclopramide Hcl18$113
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$93
Gabapentin13$82
Doxycycline Hyclate11$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$494$17,62526 claims
PfizerEliquis$140$6,92112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 294 surgical providers in Ohio.

Other surgical in Portsmouth

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →